PDCD1 and hepatocellular carcinoma: Based on the inclusion criteria, 434 HCC patients who underwent anti-PD-1 inhibitors were eventually included (Fig. 1), among which 375 (86.41%) were males and 326 (75.12%) were older than 60 years.